Heather White
Chief Tech/Sci/R&D Officer at ALBIREO PHARMA, INC.
Profile
Heather White is currently the SVP-Clinical Development Operations R&D at Albireo Pharma, Inc. She previously worked as a Senior Director at Amicus Therapeutics, Inc., Vice President-Global Internal Audit at Ipsen SA, and Head-Medical Affairs at Schering-Plough Ltd.
Ms. White received her undergraduate and graduate degrees from The University of Liverpool.
Heather White active positions
| Companies | Position | Start |
|---|---|---|
| ALBIREO PHARMA, INC. | Chief Tech/Sci/R&D Officer | 2023-03-01 |
Former positions of Heather White
| Companies | Position | End |
|---|---|---|
| AMICUS THERAPEUTICS, INC. | Director/Board Member | - |
Schering-Plough Ltd.
 Schering-Plough Ltd. Pharmaceuticals: MajorHealth Technology Schering-Plough Ltd. manufactures and distributes pharmaceutical products. Its products include medicines for vascular diseases, oncology, opioid tendency, sexual health and virology. The company was founded on December 31, 1884 and is headquartered in Walton, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
| IPSEN | Comptroller/Controller/Auditor | - |
Training of Heather White
| The University of Liverpool | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| IPSEN | Health Technology |
| Private companies | 2 |
|---|---|
Schering-Plough Ltd.
Schering-Plough Ltd. Pharmaceuticals: MajorHealth Technology Schering-Plough Ltd. manufactures and distributes pharmaceutical products. Its products include medicines for vascular diseases, oncology, opioid tendency, sexual health and virology. The company was founded on December 31, 1884 and is headquartered in Walton, the United Kingdom. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Heather White